# A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer

> **NCT01265927** · PHASE1 · COMPLETED · sponsor: **Indiana University** · enrollment: 10 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** GRN163L in combination with trastuzumab

## Key facts

- **NCT ID:** NCT01265927
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-08
- **Final completion:** 2015-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2015-10-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01265927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01265927, "A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01265927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*